33099-08-0

Basic information

• Product Name: N-Cbz-N-methyl-L-leucine
• Synonyms: N-carbobenzyloxy-N-methyl-L-leucine;(S)-2-((benzyloxycarbonyl)(methyl)amino)-4-methylpentanoic acid;Z-N-Me-L-Leu-OH;(2S)-2-[[(benzyloxy)carbonyl](Methyl)aMino]-4-Methylpentanoic acid;Cbz-N-Methyl-L-leucine;Cbz-N-Me-L-Leu-OH;Z-N-methyl-L-leucine99%;BENZYLOXYCARBONYL-N-METHYL-L-LEUCINE
• CAS NO: 33099-08-0
• Molecular Formula: C₁₅H₂₁NO₄
• Molecular Weight: 279.33
• Product Categories: Amino Acid Derivatives
• Mol File: 33099-08-0.mol

Chemical Properties

• Melting Point: 74-75 °C
• Boiling Point: 419.449 °C at 760 mmHg
• Flash Point: 207.475 °C
• Appearance: /
• Density: 1.145 g/cm³
• Vapor Pressure: 8.72E-08mmHg at 25°C
• Refractive Index: 1.528
• Storage Temp.: -15°C
• PKA: 4.02±0.21(Predicted)
• BRN: 1993458
• CAS DataBase Reference: N-Cbz-N-methyl-L-leucine(CAS DataBase Reference)
• NIST Chemistry Reference: N-Cbz-N-methyl-L-leucine(33099-08-0)
• EPA Substance Registry System: N-Cbz-N-methyl-L-leucine(33099-08-0)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 33099-08-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-Cbz-N-methyl-L-leucine is used as a building block in the synthesis of peptides and pharmaceuticals for its ability to protect the amino group, which is crucial in the formation of stable amide bonds. This property is essential in the development of new drugs and therapeutic agents.
Used in Organic Chemistry Research:
In the field of organic chemistry, N-Cbz-N-methyl-L-leucine serves as a valuable research compound, enabling scientists to explore novel synthetic pathways and understand the reactivity and stability of various chemical groups.
Used in Biochemistry and Biotechnology:
N-Cbz-N-methyl-L-leucine is utilized as a component in the study of protein structure and function, as well as in the development of biotechnological applications, such as enzyme catalysis and the creation of novel biomaterials.
Used in Neurological Disorder Treatment:
N-Cbz-N-methyl-L-leucine is being investigated for its potential use in the treatment of neurological disorders, given its role in peptide synthesis and the possibility of modulating neuroprotective or neuroregenerative pathways.
Used in Cancer Therapy Development:
N-Cbz-N-methyl-L-leucine is also being studied for its potential applications in cancer therapy, where it may contribute to the development of targeted drugs or enhance the efficacy of existing treatments by leveraging its properties in peptide synthesis and drug design.

InChI:InChI=1/C15H21NO4/c1-11(2)9-13(14(17)18)16(3)15(19)20-10-12-7-5-4-6-8-12/h4-8,11,13H,9-10H2,1-3H3,(H,17,18)/t13-/m0/s1

Upstream product

• 2018-66-8 Z-Leu-OH 
• 74-88-4 methyl iodide 
• 117194-65-7 Z-(Me)Leu-O-(t-Bu) 
• 77-78-1 dimethyl sulfate 
• 66866-66-8 phenylmethyl (4S)-4-(2-methylpropyl)-5-oxo-1,3-oxazolidine-3-carboxylate 
• 61-90-5 L-leucine 
• 501-53-1 benzyl chloroformate 
• 53363-88-5 methyl N-benzyloxycarbonyl-N-methyl-L-leucinate 

Downstream Products

• 109745-88-2 Z-Me-Leu-Val-OMe 
• 117194-55-5 Z-Val-(Me)Leu-O-(t-Bu) 
• 89537-02-0 Z-(Me)Leu-(Me)Val-O-(t-Bu) 
• 128892-34-2 Z-MeLeu-MeVal-OMe 
• 86645-64-9 iBuOCO-Lys(Z)-OMe 
• 112277-28-8 Z-MeLeu-Lys(Z)-OMe 
• 63236-33-9 Z-DL-(Me)Leu-Ala-OMe 
• 117290-42-3 Z-(Me)Leu-Ala-OMe 
• 117194-56-6 Z-(Me)Leu-Val-(Me)Leu-O-(t-Bu) 
• 117194-54-4 Z-(Me)Leu-Val-(Me)Leu-Ala-D-Ala-(Me)Leu-(Me)Leu-(Me)Val-O-(t-Bu) 
• 89537-04-2 N-(Benzyloxycarbonyl)-N-methyl-(S)-leucyl-N-methyl-(S)-leucyl-N-methyl-(S)-valin-tert-butylester 
• 117194-63-5 Z-(Me)Leu-Ala-D-Ala-(Me)Leu-(Me)Leu-(Me)Val-O-(t-Bu) 
• 144852-24-4 ((S)-1-Carbamoyl-3-methyl-butyl)-methyl-carbamic acid benzyl ester 
• 117290-44-5 Bz-(Me)Leu-L-Ala-OMe 

Relevant articles and documents

Synthesis of dysideaproline e using organocatalysis

(S)-4,4-Dichloro-3-methylbutanoic acid was prepared in 51% overall yield from commercially available starting materials using an organocatalytic transfer hydrogenation to 4,4-dichloro-3-methylbut-2-enal in the key step. The (S)-dichloro acid was used as an intermediate in the first total synthesis of dysideaproline E and a diastereomer confirming the structure of the natural product.

Total synthesis of the chlorinated marine natural product dysamide B

Two approaches to the synthesis of (2S,4S)-5,5-dichloroleucine are compared, and the parent amino acid was used in the first total synthesis of the polychlorinaled marine natural product, dysamide B. A key step was the lead tetraacetate-mediated decarboxylation of an α,α-dichloro acid in the presence of 1,4-cyclohexadiene to generate the dichloromethyl group.

Effective methods for the synthesis of N-methyl β-amino acids from all twenty common α-amino acids using 1,3-oxazolidin-5-ones and 1,3-oxazinan-6-ones

N-Methyl β-amino acids are generally required for application in the synthesis of potentially bioactive modified peptides and other oligomers. Previous work highlighted the reductive cleavage of 1,3-oxazolidin-5-ones to synthesise N-methyl α-amino acids. Starting from α-amino acids, two approaches were used to prepare the corresponding N-methyl β-amino acids. First, α-amino acids were converted to N-methyl α-amino acids by the so-called '1,3-oxazolidin-5-one strategy', and these were then homologated by the Arndt-Eistert procedure to afford N-protected N-methyl β-amino acids derived from the 20 common α-amino acids. These compounds were prepared in yields of 23-57% (relative to N-methyl α-amino acid). In a second approach, twelve N-protected α-amino acids could be directly homologated by the Arndt-Eistert procedure, and the resulting β-amino acids were converted to the 1,3-oxazinan-6-ones in 30-45% yield. Finally, reductive cleavage afforded the desired N-methyl β-amino acids in 41-63% yield. One sterically congested β-amino acid, 3-methyl-3-aminobutanoic acid, did give a high yield (95%) of the 1,3-oxazinan-6-one (65), and subsequent reductive cleavage gave the corresponding AIBN-derived N-methyl β-amino acid 61 in 71% yield (Scheme 2). Thus, our protocols allow the ready preparation of all N-methyl β-amino acids derived from the 20 proteinogenic α-amino acids.

Boronic ester and acid compounds, synthesis and uses

Disclosed herein are boronic ester and acid compounds, their synthesis and uses. More specifically, disclosed herein is a method for reducing the rate of degradation of proteins in an animal comprising contacting cells of the animal with certain boronic ester and acid compounds.

A simple and rapid protocol for N-methyl-α-amino acids

A two step strategy for optically pure N-Protected-N-methyl-α-amino acids starting from N-protected-α-amino acids via reductive cleavage of oxazolidinones using NaCNBH3/TMSCl is described.

Synthesis and biological activities of [N-MeLeu5]- and [N-MePhe5]- didemnin B

Based on information from X-ray, NMR, and SAR data, the N,O-diMeTyr5 unit of didemnin B was believed to be important for biological activity. To determine the importance of aromaticity and the role of the methoxy group in this unit, two analogs

BORONIC ESTER AND ACID COMPOUNDS

Disclosed herein is a method for reducing the rate of degradation of proteins in an animal comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses.

Dolastatins. 26. Synthesis and stereochemistry of dolastatin 11

The first synthesis of dolastatin 11, a potent antineoplastic agent from the sea hare Dolabella auricularia, confirmed the proposed structure and established the last configuration in this natural product and in dolastatin 12, majusculamide C, and 57-norm

Aldehyde derivatives and their use as calpain inhibitors

Aldehyde derivatives with a specific calpain inhibiting activity and a platelet-aggregation inhibiting effect with formula (I) or formula (II): wherein R1 represents an aromatic hydrocarbon group, a heterocyclic group, or a group of-X-R3 in which X represents O,-S(O)m-(m = 0, 1, or 2), and R3 represents an aromatic hydrocarbon group, a heterocyclic group, or an alkyl group; Z represents R?-Y-or R?O-CH(R?)-in which Y represents a 3-to 7-membered nitrogen-containing saturated heterocyclic group, or a single cyclic saturated hydrocarbon group, R? represents an alkyl group, an alkenyl group, an alkynyl group, an acyl group, a sulfonyl group, an alkoxycarbonyl group, a carbamoyl group, or a thiocarbamoyl group, R? represents hydrogen, an alkyl group, or an aromatic hydrocarbon group, and R? represents an acyl group, a carbamoyl group, a thiocarbamoyl group, or an alkyl group; and n is an integer of 1 to 5. wherein R?, R?, R?, and R1? are defined in the specification.

SYNTHESIS OF TWO LINEAR OCTAPEPTIDE FRAGMENTS OF CYCLOSPORIN BY STEPWISE AND FRAGMENT CONDENSATION STRATEGIES

The octapeptide Z-(Me)Leu-Val-(Me)Leu-Ala-D-Ala-(Me)Leu-(Me)Leu-(Me)Val-O(t-Bu) was prepared by stepwise elongation starting from H-(Me)Val-O(t-Bu).Diphenylphosphinic mixed anhydrides were preferentially used throughout as they gave high yields of optical